Published in Am J Transl Res on July 27, 2012
Tumor vasculature targeting and imaging in living mice with reduced graphene oxide. Biomaterials (2013) 1.26
PET imaging of CD105/endoglin expression with a ⁶¹/⁶⁴Cu-labeled Fab antibody fragment. Eur J Nucl Med Mol Imaging (2013) 1.03
In Vivo Integrity and Biological Fate of Chelator-Free Zirconium-89-Labeled Mesoporous Silica Nanoparticles. ACS Nano (2015) 1.03
Iron oxide decorated MoS2 nanosheets with double PEGylation for chelator-free radiolabeling and multimodal imaging guided photothermal therapy. ACS Nano (2015) 0.99
Positron emission tomography imaging of tumor angiogenesis with a (61/64)Cu-labeled F(ab')(2) antibody fragment. Mol Pharm (2013) 0.97
Interrogating tumor metabolism and tumor microenvironments using molecular positron emission tomography imaging. Theranostic approaches to improve therapeutics. Pharmacol Rev (2013) 0.89
Positron emission tomography imaging of CD105 expression in a rat myocardial infarction model with (64)Cu-NOTA-TRC105. Am J Nucl Med Mol Imaging (2013) 0.89
Positron emission tomography imaging of angiogenesis in a murine hindlimb ischemia model with 64Cu-labeled TRC105. Mol Pharm (2013) 0.89
Chemoenzymatic strategy for the synthesis of site-specifically labeled immunoconjugates for multimodal PET and optical imaging. Bioconjug Chem (2014) 0.88
Bimodal imaging probes for combined PET and OI: recent developments and future directions for hybrid agent development. Biomed Res Int (2014) 0.88
PET Imaging of Abdominal Aortic Aneurysm with 64Cu-Labeled Anti-CD105 Antibody Fab Fragment. J Nucl Med (2015) 0.86
Imaging tumor angiogenesis in breast cancer experimental lung metastasis with positron emission tomography, near-infrared fluorescence, and bioluminescence. Angiogenesis (2013) 0.85
Zirconium-89 labeled antibodies: a new tool for molecular imaging in cancer patients. Biomed Res Int (2014) 0.84
New radiotracers for imaging of vascular targets in angiogenesis-related diseases. Adv Drug Deliv Rev (2014) 0.83
HaloTag as a reporter gene: positron emission tomography imaging with (64)Cu-labeled second generation HaloTag ligands. Am J Transl Res (2013) 0.81
Intraoperative targeted optical imaging: a guide towards tumor-free margins in cancer surgery. Curr Pharm Biotechnol (2013) 0.80
Cerenkov Radiation Induced Photodynamic Therapy Using Chlorin e6-Loaded Hollow Mesoporous Silica Nanoparticles. ACS Appl Mater Interfaces (2016) 0.80
Engineering Intrinsically Zirconium-89 Radiolabeled Self-Destructing Mesoporous Silica Nanostructures for In Vivo Biodistribution and Tumor Targeting Studies. Adv Sci (Weinh) (2016) 0.79
Pravastatin stimulates angiogenesis in a murine hindlimb ischemia model: a positron emission tomography imaging study with (64)Cu-NOTA-TRC105. Am J Transl Res (2013) 0.78
Multimodality imaging of RNA interference. Curr Med Chem (2013) 0.75
Molecular Imaging of Angiogenesis in Cardiac Regeneration. Curr Cardiovasc Imaging Rep (2016) 0.75
Intrinsically (89)Zr-labeled Gd2O2S:Eu nanophosphors with high in vivo stability for dual-modality imaging. Am J Transl Res (2016) 0.75
SPECT and PET imaging of angiogenesis and arteriogenesis in pre-clinical models of myocardial ischemia and peripheral vascular disease. Eur J Nucl Med Mol Imaging (2016) 0.75
A Pretargeted Approach for the Multimodal PET/NIRF Imaging of Colorectal Cancer. Theranostics (2016) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
A tabulated summary of the FDG PET literature. J Nucl Med (2001) 4.37
Multimodality molecular imaging of tumor angiogenesis. J Nucl Med (2008) 3.99
Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther (2010) 3.42
Standardized methods for the production of high specific-activity zirconium-89. Nucl Med Biol (2009) 2.77
A molecular imaging primer: modalities, imaging agents, and applications. Physiol Rev (2012) 2.76
Endoglin (CD105): a marker of tumor vasculature and potential target for therapy. Clin Cancer Res (2008) 2.75
Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients. Clin Cancer Res (2006) 2.71
Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease. Chem Rev (2010) 2.70
Monitoring response to anticancer therapy by targeting microbubbles to tumor vasculature. Clin Cancer Res (2007) 2.19
PET of vascular endothelial growth factor receptor expression. J Nucl Med (2006) 2.18
Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine. Nat Protoc (2010) 2.09
In vitro and in vivo characterization of 64Cu-labeled Abegrin, a humanized monoclonal antibody against integrin alpha v beta 3. Cancer Res (2006) 2.09
Imaging of integrins as biomarkers for tumor angiogenesis. Curr Pharm Des (2008) 2.04
p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging. Eur J Nucl Med Mol Imaging (2009) 2.01
Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours. Cardiovasc Res (2009) 1.78
Positron emission tomography imaging of CD105 expression during tumor angiogenesis. Eur J Nucl Med Mol Imaging (2011) 1.70
Endoglin-targeted cancer therapy. Curr Drug Deliv (2011) 1.65
Cerenkov imaging - a new modality for molecular imaging. Am J Nucl Med Mol Imaging (2012) 1.57
Imaging of integrin alphavbeta3 expression. Cancer Metastasis Rev (2008) 1.56
Positron emission tomography imaging of CD105 expression with 89Zr-Df-TRC105. Eur J Nucl Med Mol Imaging (2011) 1.50
PET tracers based on Zirconium-89. Curr Radiopharm (2011) 1.48
Evaluation of desferal as a bifunctional chelating agent for labeling antibodies with Zr-89. Int J Rad Appl Instrum A (1992) 1.43
A new PET tracer specific for vascular endothelial growth factor receptor 2. Eur J Nucl Med Mol Imaging (2007) 1.43
The clinical use of PET with (11)C-acetate. Am J Nucl Med Mol Imaging (2011) 1.43
Positron emission tomography (PET) imaging with (18)F-based radiotracers. Am J Nucl Med Mol Imaging (2011) 1.41
Positron Emission Tomography and Near-Infrared Fluorescence Imaging of Vascular Endothelial Growth Factor with Dual-Labeled Bevacizumab. Am J Nucl Med Mol Imaging (2012) 1.41
Positron emission tomography imaging of CD105 expression with a 64Cu-labeled monoclonal antibody: NOTA is superior to DOTA. PLoS One (2011) 1.36
Endoglin is a suitable target for efficient imaging of solid tumors: in vivo evidence in a canine mammary carcinoma model. Clin Cancer Res (2000) 1.35
Immuno-positron emission tomography: shedding light on clinical antibody therapy. Cancer Biother Radiopharm (2010) 1.35
Multimodality imaging of vascular endothelial growth factor and vascular endothelial growth factor receptor expression. Front Biosci (2007) 1.33
Are quantum dots ready for in vivo imaging in human subjects? Nanoscale Res Lett (2007) 1.30
Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies. Clin Cancer Res (1999) 1.29
Quantitative radioimmunoPET imaging of EphA2 in tumor-bearing mice. Eur J Nucl Med Mol Imaging (2007) 1.26
How to study optimal timing of PET/CT for monitoring of cancer treatment. Am J Nucl Med Mol Imaging (2011) 1.19
Targeting vascular endothelium with avidin microbubbles. Ultrasound Med Biol (2005) 1.19
ImmunoSPECT and immunoPET of IGF-1R expression with the radiolabeled antibody R1507 in a triple-negative breast cancer model. J Nucl Med (2010) 1.14
(18)F-FDG PET in sarcoma treatment response imaging. Am J Nucl Med Mol Imaging (2011) 1.12
Imaging of tumour neovasculature by targeting the TGF-beta binding receptor endoglin. Eur J Cancer (2000) 1.10
Perfusion of 99Tcm-labeled CD105 Mab into kidneys from patients with renal carcinoma suggests that CD105 is a promising vascular target. Int J Cancer (2004) 1.02
In vivo near-infrared fluorescence imaging of CD105 expression during tumor angiogenesis. Eur J Nucl Med Mol Imaging (2011) 1.02
Peptoid-based PET imaging of vascular endothelial growth factor receptor (VEGFR) expression. Am J Nucl Med Mol Imaging (2011) 1.01
Prediction of metastasis risk (11 year follow-up) using VEGF-R1, VEGF-R2, Tie-2/Tek and CD105 expression in breast cancer (n=905). Br J Cancer (2004) 1.00
Radionuclide imaging of tumor angiogenesis. Cancer Biother Radiopharm (2009) 0.99
(18)F-FDG PET/CT: timing for evaluation of response to therapy remains a clinical challenge. Am J Nucl Med Mol Imaging (2011) 0.97
MR imaging of tumor angiogenesis using sterically stabilized Gd-DTPA liposomes targeted to CD105. Eur J Radiol (2008) 0.96
Current imaging strategies in rheumatoid arthritis. Am J Nucl Med Mol Imaging (2012) 0.94
In a "nutshell": intrinsically radio-labeled quantum dots. Am J Nucl Med Mol Imaging (2012) 0.88
Peptoid and Positron Emission Tomography: an Appealing Combination. Am J Nucl Med Mol Imaging (2011) 0.86
Molecular imaging of insulin-like growth factor 1 receptor in cancer. Am J Nucl Med Mol Imaging (2012) 0.83
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med (2015) 8.80
In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. Nat Nanotechnol (2006) 6.93
Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med (2013) 6.17
Circulation and long-term fate of functionalized, biocompatible single-walled carbon nanotubes in mice probed by Raman spectroscopy. Proc Natl Acad Sci U S A (2008) 4.89
Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J Clin Oncol (2009) 3.51
Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol (2005) 3.12
Quantitative PET imaging of tumor integrin alphavbeta3 expression with 18F-FRGD2. J Nucl Med (2006) 2.65
Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Transl Med (2011) 2.51
(64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression. J Nucl Med (2007) 2.50
Prevalence of unruptured cerebral aneurysms in Chinese adults aged 35 to 75 years: a cross-sectional study. Ann Intern Med (2013) 2.23
CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res (2008) 2.13
A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clin Cancer Res (2008) 1.99
Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol (2003) 1.97
Dynamic ventilation imaging from four-dimensional computed tomography. Phys Med Biol (2006) 1.80
Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst (2010) 1.73
Applications of gold nanoparticles in cancer nanotechnology. Nanotechnol Sci Appl (2008) 1.71
Positron emission tomography imaging of CD105 expression during tumor angiogenesis. Eur J Nucl Med Mol Imaging (2011) 1.70
A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer. Clin Cancer Res (2012) 1.64
Phase II clinical trial design: methods in translational research from the Genitourinary Committee at the Eastern Cooperative Oncology Group. Clin Cancer Res (2006) 1.60
Structural basis of EZH2 recognition by EED. Structure (2007) 1.58
cRGD-functionalized, DOX-conjugated, and ⁶⁴Cu-labeled superparamagnetic iron oxide nanoparticles for targeted anticancer drug delivery and PET/MR imaging. Biomaterials (2011) 1.56
A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Cancer Res (2008) 1.56
Dual-modality optical and positron emission tomography imaging of vascular endothelial growth factor receptor on tumor vasculature using quantum dots. Eur J Nucl Med Mol Imaging (2008) 1.55
In vivo targeting and imaging of tumor vasculature with radiolabeled, antibody-conjugated nanographene. ACS Nano (2012) 1.53
Positron emission tomography imaging of CD105 expression with 89Zr-Df-TRC105. Eur J Nucl Med Mol Imaging (2011) 1.50
Response to antiangiogenesis therapy in a patient with advanced adult-type testicular granulosa cell tumor. Oncology (Williston Park) (2009) 1.48
PET tracers based on Zirconium-89. Curr Radiopharm (2011) 1.48
Molecular imaging and therapy of cancer with radiolabeled nanoparticles. Nano Today (2009) 1.47
microPET of tumor integrin alphavbeta3 expression using 18F-labeled PEGylated tetrameric RGD peptide (18F-FPRGD4). J Nucl Med (2007) 1.46
Near-infrared fluorescence imaging of tumor integrin alpha v beta 3 expression with Cy7-labeled RGD multimers. Mol Imaging Biol (2006) 1.46
A new PET tracer specific for vascular endothelial growth factor receptor 2. Eur J Nucl Med Mol Imaging (2007) 1.43
Positron Emission Tomography and Near-Infrared Fluorescence Imaging of Vascular Endothelial Growth Factor with Dual-Labeled Bevacizumab. Am J Nucl Med Mol Imaging (2012) 1.41
A phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer. Clin Cancer Res (2005) 1.39
18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer. J Nucl Med (2006) 1.37
Positron emission tomography imaging of CD105 expression with a 64Cu-labeled monoclonal antibody: NOTA is superior to DOTA. PLoS One (2011) 1.36
Quantification of regional ventilation from treatment planning CT. Int J Radiat Oncol Biol Phys (2005) 1.36
In vivo tumor targeting and image-guided drug delivery with antibody-conjugated, radiolabeled mesoporous silica nanoparticles. ACS Nano (2013) 1.34
Graphene: a versatile nanoplatform for biomedical applications. Nanoscale (2012) 1.32
A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802. Med Oncol (2011) 1.30
Noninvasive de novo imaging of human embryonic stem cell-derived teratoma formation. Cancer Res (2009) 1.28
Mouse corneal lymphangiogenesis model. Nat Protoc (2011) 1.27
Multifunctional unimolecular micelles for cancer-targeted drug delivery and positron emission tomography imaging. Biomaterials (2012) 1.27
Multimodality molecular imaging of glioblastoma growth inhibition with vasculature-targeting fusion toxin VEGF121/rGel. J Nucl Med (2007) 1.26
Tumor vasculature targeting and imaging in living mice with reduced graphene oxide. Biomaterials (2013) 1.26
Collaborative interplay between FGF-2 and VEGF-C promotes lymphangiogenesis and metastasis. Proc Natl Acad Sci U S A (2012) 1.23
Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin: a phase I, pharmacokinetic, and biological correlative study. Clin Cancer Res (2008) 1.21
Copper-catalyzed synthesis of N-fused heterocycles through regioselective 1,2-aminothiolation of 1,1-dibromoalkenes. Org Lett (2010) 1.20
Beyond taxanes: a review of novel agents that target mitotic tubulin and microtubules, kinases, and kinesins. Clin Adv Hematol Oncol (2009) 1.18
Multimodality molecular imaging of CD105 (Endoglin) expression. Int J Clin Exp Med (2010) 1.16
Integrin alphavbeta3-targeted radioimmunotherapy of glioblastoma multiforme. Clin Cancer Res (2008) 1.14